Cost-effectiveness analysis of nivolumab plus ipilimumab chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

Introduction: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab (NI) versus pemetrexed plus cisplatin/carboplatin (C) as the first-line treatment for unresectable malignant pleural mesothelioma (MPM) from the perspective of US payers. Methods: A 10-year partitioned survival mo...

詳細記述

書誌詳細

出版年:	Therapeutic Advances in Medical Oncology
主要な著者:	Liu Yang, Xueqiong Cao, Na Li, Bin Zheng, Maobai Liu, Hongfu Cai
フォーマット:	論文
言語:	英語
出版事項:	SAGE Publishing 2022-08-01
オンライン･アクセス:	https://doi.org/10.1177/17588359221116604